ABBV - AbbVie
175.58
| Index: | S&P 500 | P/E: | 61.23 | EPS (ttm): | 2.87 | Insider Own: | 0.08% | Shs Outstand: | 1.77B | Perf Week: | 1.27% |
| Market Cap: | 317.62B | Forward P/E: | 14.39 | EPS next Y: | 12.20 | Insider Trans: | -19.53% | Shs Float: | 1.77B | Perf Month: | 4.66% |
| Income(ttm): | 5.08B | PEG: | 7.29 | EPS next Q: | 2.98 | Inst Own: | 72.95% | Short Float: | 1.09% | Perf Quarter: | -9.42% |
| Revenue(ttm): | 55.53B | P/S: | 5.72 | EPS this Y: | -1.53% | Inst Trans: | -0.08% | Short Ratio: | 3.16 | Perf Half Y: | 1.64% |
| Book/sh: | 3.41 | P/B: | 51.44 | EPS next Y: | 11.53% | ROA: | 3.63% | Short Interest: | 19.32M | Perf Year: | 15.75% |
| Cash/sh: | 4.03 | P/C: | 43.60 | EPS next 5Y: | 8.40% | ROE: | 56.06% | 52W Range: | 151.29 - 207.32 | Perf YTD: | 13.30% |
| Dividend Est.: | 6.17 (3.51%) | P/FCF: | 20.38 | EPS past 5Y: | -5.77% | ROI: | 7.87% | 52W High: | -15.31% | Beta: | 0.58 |
| Dividend TTM: | 6.20 (3.53%) | Quick Ratio: | 0.54 | Sales past 5Y: | 11.76% | Gross Margin: | 69.87% | 52W Low: | 16.06% | ATR (14): | 4.01 |
| Dividend Ex-Date: | Jan 15, 2025 | Current Ratio: | 0.65 | EPS Y/Y TTM: | -21.61% | Oper. Margin: | 30.61% | RSI (14): | 46.96 | Volatility: | 2.63% 2.13% |
| Employees: | 50000 | Debt/Eq: | 11.78 | Sales Y/Y TTM: | 0.72% | Profit Margin: | 9.15% | Recom: | 1.81 | Target Price: | 204.08 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 9.70 | EPS Q/Q: | -12.27% | Payout: | 220.33% | Rel Volume: | 2.89 | Prev Close: | 171.52 |
| Sales Surprise: | 1.24% | EPS Surprise: | 2.74% | Sales Q/Q: | 3.83% | Earnings: | Oct 30 BMO | Avg Volume: | 6.12M | Price: | 175.58 |
| SMA20: | -0.62% | SMA50: | -3.93% | SMA200: | -1.82% | Undervalued: 16.23% | Volume: | 17,695,727 | Change: | 2.37% | |
Graham Classic formula value: 65.2
(P/E=8 * 1g) Min value: 42.27
(current P/E * 2g) Max value: 201.09
Average value: 102.85
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.